AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 64 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $6,248,000 | -38.3% | 776,094 | -42.6% | 0.01% | -45.5% |
| Q4 2018 | $10,125,000 | -31.0% | 1,351,790 | -11.8% | 0.01% | -21.4% |
| Q3 2018 | $14,665,000 | -9.1% | 1,532,401 | +0.5% | 0.01% | -12.5% |
| Q2 2018 | $16,139,000 | +8.1% | 1,525,447 | +1.4% | 0.02% | +6.7% |
| Q1 2018 | $14,931,000 | +98.1% | 1,505,098 | +8.0% | 0.02% | +114.3% |
| Q4 2017 | $7,539,000 | +14.8% | 1,393,439 | +0.6% | 0.01% | 0.0% |
| Q3 2017 | $6,565,000 | +22.4% | 1,385,067 | -0.8% | 0.01% | +16.7% |
| Q2 2017 | $5,363,000 | -50.5% | 1,396,667 | -4.0% | 0.01% | -50.0% |
| Q1 2017 | $10,836,000 | +72.3% | 1,454,529 | +0.6% | 0.01% | +71.4% |
| Q4 2016 | $6,289,000 | -31.1% | 1,445,713 | +1.5% | 0.01% | -30.0% |
| Q3 2016 | $9,131,000 | +36.5% | 1,424,947 | +2.7% | 0.01% | +42.9% |
| Q2 2016 | $6,688,000 | – | 1,388,079 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 340,679 | $3,604,000 | 1.39% |
| Nantahala Capital Management | 2,213,052 | $23,414,000 | 0.95% |
| SCP Investment, LP | 156,137 | $1,652,000 | 0.82% |
| SPHERA FUNDS MANAGEMENT LTD. | 509,118 | $5,386,000 | 0.74% |
| DELTEC ASSET MANAGEMENT LLC | 151,781 | $1,606,000 | 0.32% |
| Rock Springs Capital Management LP | 650,000 | $6,877,000 | 0.26% |
| Orbimed Advisors | 1,865,524 | $19,737,000 | 0.24% |
| Baker Brothers Advisors | 1,387,872 | $14,684,000 | 0.11% |
| EAM Investors, LLC | 56,726 | $600,000 | 0.10% |
| Stanley-Laman Group, Ltd. | 35,036 | $371,000 | 0.08% |